226 related articles for article (PubMed ID: 23688189)
1. IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma.
Kuijjer ML; Peterse EF; van den Akker BE; Briaire-de Bruijn IH; Serra M; Meza-Zepeda LA; Myklebost O; Hassan AB; Hogendoorn PC; Cleton-Jansen AM
BMC Cancer; 2013 May; 13():245. PubMed ID: 23688189
[TBL] [Abstract][Full Text] [Related]
2. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E
Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861
[TBL] [Abstract][Full Text] [Related]
3. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
Flanigan SA; Pitts TM; Newton TP; Kulikowski GN; Tan AC; McManus MC; Spreafico A; Kachaeva MI; Selby HM; Tentler JJ; Eckhardt SG; Leong S
Clin Cancer Res; 2013 Nov; 19(22):6219-29. PubMed ID: 24045180
[TBL] [Abstract][Full Text] [Related]
4. TGF-β-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells.
Schedlich LJ; Yenson VM; Baxter RC
Mol Cell Endocrinol; 2013 Sep; 377(1-2):56-64. PubMed ID: 23831640
[TBL] [Abstract][Full Text] [Related]
5. Assessment of GSK1904529A as a promising anti-osteosarcoma agent.
Fei HD; Yuan Q; Mao L; Chen FL; Cui ZH; Tao S; Ji F
Oncotarget; 2017 Jul; 8(30):49646-49654. PubMed ID: 28572530
[TBL] [Abstract][Full Text] [Related]
6. IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells.
Rodrigues Alves APN; Fernandes JC; Fenerich BA; Coelho-Silva JL; Scheucher PS; Simões BP; Rego EM; Ridley AJ; Machado-Neto JA; Traina F
Cancer Lett; 2019 Aug; 456():59-68. PubMed ID: 31042587
[TBL] [Abstract][Full Text] [Related]
7. Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.
Wahner Hendrickson AE; Haluska P; Schneider PA; Loegering DA; Peterson KL; Attar R; Smith BD; Erlichman C; Gottardis M; Karp JE; Carboni JM; Kaufmann SH
Cancer Res; 2009 Oct; 69(19):7635-43. PubMed ID: 19789352
[TBL] [Abstract][Full Text] [Related]
8. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.
King ER; Zu Z; Tsang YT; Deavers MT; Malpica A; Mok SC; Gershenson DM; Wong KK
Gynecol Oncol; 2011 Oct; 123(1):13-8. PubMed ID: 21726895
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-b as Involved in the Pathogenesis of Osteosarcoma.
Yang R; Piperdi S; Zhang Y; Zhu Z; Neophytou N; Hoang BH; Mason G; Geller D; Dorfman H; Meyers PA; Healey JH; Phinney DG; Gorlick R
Clin Orthop Relat Res; 2016 Jan; 474(1):178-89. PubMed ID: 26463566
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor.
Zeng X; Zhang H; Oh A; Zhang Y; Yee D
Breast Cancer Res Treat; 2012 May; 133(1):117-26. PubMed ID: 21850397
[TBL] [Abstract][Full Text] [Related]
11. The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells.
Catalano R; Giardino E; Treppiedi D; Mangili F; Morelli V; Elli FM; Serban AL; Luconi M; Mannelli M; Spada A; Arosio M; Mantovani G; Peverelli E
Cancer Lett; 2021 Jan; 497():77-88. PubMed ID: 33075426
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.
Zhang H; Pelzer AM; Kiang DT; Yee D
Cancer Res; 2007 Jan; 67(1):391-7. PubMed ID: 17210722
[TBL] [Abstract][Full Text] [Related]
14. Cell surface receptor expression patterns in osteosarcoma.
Hassan SE; Bekarev M; Kim MY; Lin J; Piperdi S; Gorlick R; Geller DS
Cancer; 2012 Feb; 118(3):740-9. PubMed ID: 21751203
[TBL] [Abstract][Full Text] [Related]
15. Chimaphilin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines through insulin-like growth factor-I receptor (IGF-IR) signaling.
Daqian W; Chuandong W; Xinhua Q; Songtao A; Kerong D
Chem Biol Interact; 2015 Jul; 237():25-30. PubMed ID: 25980584
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.
Hu YP; Patil SB; Panasiewicz M; Li W; Hauser J; Humphrey LE; Brattain MG
Cancer Res; 2008 Oct; 68(19):8004-13. PubMed ID: 18829558
[TBL] [Abstract][Full Text] [Related]
17. Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor.
Vincent EE; Elder DJ; Curwen J; Kilgour E; Hers I; Tavaré JM
PLoS One; 2013; 8(6):e66963. PubMed ID: 23826179
[TBL] [Abstract][Full Text] [Related]
18. No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone.
Peterse EF; Cleven AH; De Jong Y; Briaire-de Bruijn I; Fletcher JA; Danen EH; Cleton-Jansen AM; Bovée JV
BMC Cancer; 2016 Jul; 16():475. PubMed ID: 27418340
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of insulin-like growth factor-1 receptor inhibition in head and neck squamous cell carcinoma.
Lehman CE; Khalil AA; Axelrod MJ; Dougherty MI; Schoeff SS; Taniguchi LE; Mendez RE; David AP; McGarey PO; Hubbard MA; Donaldson L; Frierson HF; Stelow EB; Bekiranov S; Wulfkuhle JD; Petricoin EF; Gioeli DG; Jameson MJ
Laryngoscope; 2020 Jun; 130(6):1470-1478. PubMed ID: 31433065
[TBL] [Abstract][Full Text] [Related]
20. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
Ji QS; Mulvihill MJ; Rosenfeld-Franklin M; Cooke A; Feng L; Mak G; O'Connor M; Yao Y; Pirritt C; Buck E; Eyzaguirre A; Arnold LD; Gibson NW; Pachter JA
Mol Cancer Ther; 2007 Aug; 6(8):2158-67. PubMed ID: 17671083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
